CD19 and non-Hodgkin lymphoma: Celgene also launched phase III trials the same year to test its anti-CD19 CAR-T in Non-Hodgkin’s Lymphoma (NCT03575351) and BCMA-CAR T in multiple myeloma, (NCT03651128) in comparison to standard therapies (salvage chemotherapy and ASCT or later-generation Imids/proteasome inhibitors and/or daratumumab, respectively).